Progressive Multifocal Leukoencephalopathy - Epidemiology Forecast - 2032

This ‘Progressive Multifocal Leukoencephalopathy (PML) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of progressive multifocal leukoencephalopathy (PML) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Progressive Multifocal Leukoencephalopathy (PML): Disease Understanding

Progressive Multifocal Leukoencephalopathy (PML) Overview

Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus (JCV), involving infection of white matter (principally oligodendrocytes) and neurons in the brain and leading to irreversible demyelination and neuroaxonal damage.

The immunosuppressive conditions associated with PML are broad and heterogeneous, ranging from HIV-AIDS (relatively common before highly active antiretroviral therapy [HAART] was available) to disease-specific immunosuppressive therapies, including monoclonal antibodies. The causative agent is the polyomavirus JC which has a tropism for oligodendrocytes. The virus is widespread in up to 85% of the general adult population. Asymptomatic primary infection occurs in childhood, with the virus remaining latent in the kidneys and lymphoid tissue. With profound cellular immunosuppression, the virus reactivates and spreads to the CNS. Most common symptoms include limb weakness, cognitive deficits, speech and visual difficulties, ataxia, seizures, gait, sensory loss, and headache.

PML occurs at an estimated incidence of 0.2 per 100,000 patients with autoimmune diseases who did not have HIV or malignancy and at a very low incidence among patients with rheumatic diseases but can occur even in the absence of HIV or malignancy. The preferred diagnostic method is cerebral spinal fluid polymerase chain reaction (CSF PCR) to detect JC virus DNA. Stereotactic brain biopsy remains the reference standard for diagnosis. PML occurs almost exclusively in immunosuppressed patients, including those with AIDS (79%), hematologic malignancies (13%), organ transplants (5%), and autoimmune diseases on immunosuppressive therapy (3%). PML has rarely been reported in patients with occult immunosuppression such as hepatic cirrhosis and renal failure (Paul, 2019).

There is no specific treatment for JCV. Current treatment strategies are aimed at restoring immune function to improve survival successfully. In HIV-positive patients with PML, ART optimization is the best therapeutic option; in HIV-negative patients, removal or decrease of any potential source of immunosuppression is recommended. However, the prognosis for the majority of PML patients remains poor.

Despite the persistent risk of PML among patients with immunosuppressive conditions and a growing risk of PML among patients treated with immunomodulatory agents, no therapeutics are approved for the treatment of PML. However, the incidence and mortality of PML have decreased since the introduction of HAART, and the restoration of the host adaptive immune response has been shown to prolong survival.

Recently, genetic risk variants in patients with PML have been identified, which might help assess patients at risk, especially in those using immunosuppressant agents. However, outcomes in PML populations remain poor. Therefore, there is still a high unmet need for effective prophylaxis and treatment of PML.

Progressive Multifocal Leukoencephalopathy (PML): Epidemiology

The progressive multifocal leukoencephalopathy (PML) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted progressive multifocal leukoencephalopathy (PML) epidemiology segmented as the Diagnosed incident cases of progressive multifocal leukoencephalopathy, Age-specific cases of progressive multifocal leukoencephalopathy, and Incident cases of progressive multifocal leukoencephalopathy based on etiologies. The report includes the incident scenario of progressive multifocal leukoencephalopathy (PML) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise progressive multifocal leukoencephalopathy (PML) Epidemiology

The epidemiology segment also provides the progressive multifocal leukoencephalopathy (PML) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed incident cases of progressive multifocal leukoencephalopathy (PML) in the 7MM countries was close to 3,900 cases in 2021.

As per the estimates, the United States had the highest diagnosed incident cases of progressive multifocal leukoencephalopathy (PML) in 2021. Among the EU5 countries, Germany had the highest diagnosed incident cases of progressive multifocal leukoencephalopathy (PML) with more than 400 cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed incident cases of progressive multifocal leukoencephalopathy (PML) close to 230 cases in 2021.

Scope of the Report

• The progressive multifocal leukoencephalopathy report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• The progressive multifocal leukoencephalopathy epidemiology report and model provide an overview of the risk factors and global trends of progressive multifocal leukoencephalopathy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of progressive multifocal leukoencephalopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of progressive multifocal leukoencephalopathy.
• The report provides the segmentation of progressive multifocal leukoencephalopathy epidemiology by diagnosed incident cases of progressive multifocal leukoencephalopathy in the 7MM.
• The report provides the segmentation of the progressive multifocal leukoencephalopathy epidemiology by age-specific cases of progressive multifocal leukoencephalopathy in the 7MM.
• The report provides the segmentation of the progressive multifocal leukoencephalopathy epidemiology by incident cases of progressive multifocal leukoencephalopathy based on etiologies in the 7MM.

Report Highlights

• 11-year Forecast of progressive multifocal leukoencephalopathy epidemiology
• 7MM Coverage
• Diagnosed incident cases of progressive multifocal leukoencephalopathy
• Age-specific cases of progressive multifocal leukoencephalopathy
• Incident cases of progressive multifocal leukoencephalopathy based on etiologies

KOL Views

The publisher interviews KOLs and obtain SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What are the major factors that will drive the change in the patient population in progressive multifocal leukoencephalopathy during the forecast period (2019-2032)?
• What are the key findings pertaining to the progressive multifocal leukoencephalopathy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with progressive multifocal leukoencephalopathy across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of progressive multifocal leukoencephalopathy?
• What are the currently available treatments for progressive multifocal leukoencephalopathy?

Reasons to Buy

Progressive Multifocal Leukoencephalopathy (PML) Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global progressive multifocal leukoencephalopathy (PML) market.
• Quantify patient populations in the global progressive multifocal leukoencephalopathy market to improve product design, pricing, and launch plans.
• Understand the magnitude of the progressive multifocal leukoencephalopathy population by its diagnosed incident cases.
• Understand the magnitude of the progressive multifocal leukoencephalopathy population by its age-specific cases.
• Understand the magnitude of the progressive multifocal leukoencephalopathy (PML) population by its incident cases of progressive multifocal leukoencephalopathy based on etiologies.
• The progressive multifocal leukoencephalopathy (PML) epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The progressive multifocal leukoencephalopathy (PML) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032